A practical reference on HPLC-UV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-25 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
=== Home sleep test (HST) / home sleep apnea test (HSAT) === Sleep apnea can also be diagnosed using an in-home testing kit. The main advantage is that these record in the usual sleep environment and thus are more representative of their natural sleep than staying overnight at a lab. Home sleep testing is more accessible and less expensive than polysomnography due to long waiting periods for in-lab tests.
== Further reading == Whitten, Kenneth W.; Davis, Raymond E; Peck, M. Larry (2002). General chemistry. Fort Worth: Thomson Learning. ISBN 978-0-03-021017-4. Whitten, Kenneth W; Gailey, Kenneth D (1981). General chemistry. Philadelphia: Saunders College Pub. ISBN 978-0-03-057866-3. Petrucci, Ralph H.; Herring, F. Geoffrey; Madura, Jeffry; Bissonnette, Carey; Pearson (2017). General chemistry: principles and modern applications. Toronto: Pearson. ISBN 978-0-13-293128-1. Vogel, Arthur Israel; Furniss, B. S; Tatchell, Austin Robert (1978). Vogel's Textbook of practical organic chemistry. New York: Longman. ISBN 978-0-582-44250-4.
In a speech to Mansion House, Andrew Bailey, the governor of the Bank of England, says the UK must "rebuild relations" with the EU "while respecting the decision of the British people" who voted for Brexit. Neil Gray, Scotland's Health and Social Care Secretary, apologises to the Scottish Parliament for not attending a "wider range" of football matches after he used a chauffeur driven vehicle to attend four games at Aberdeen F.C., something he says gave the impression he was acting "more as a fan and less as a minister". 15 November – A report by the National Audit Office reveals that the Home Office "cut corners" and made "poor decisions", while under pressure to stop housing migrants in hotels, when it purchased the former HM Prison Northeye for £15m in 2023; the site was derelict and contaminated with asbestos. 10 Downing Street apologises after meat and alcohol were served at a Diwali celebration held there in October. Stephen McCabe resigns as leader of Inverclyde Council after appearing in court charged with assault and threatening behaviour. Northern Ireland Communities Minister Gordon Lyons attends a football match between Northern Ireland and Belarus despite UK government guidance that the game should not go ahead because of sanctions against Belarus over its stance over the Ukraine War.
Sources: en.wikipedia.org
== Function == The Hsp70 system interacts with extended peptide segments of proteins as well as partially folded proteins to cause aggregation of proteins in key pathways to downregulate activity. When not interacting with a substrate peptide, Hsp70 is usually in an ATP bound state. Hsp70 by itself is characterized by a very weak ATPase activity, such that spontaneous hydrolysis will not occur for many minutes. As newly synthesized proteins emerge from the ribosomes, the substrate binding domain of Hsp70 recognizes sequences of hydrophobic amino acid residues, and interacts with them. This spontaneous interaction is reversible, and in the ATP bound state Hsp70 may relatively freely bind and release peptides. However, the presence of a peptide in the binding domain stimulates the ATPase activity of Hsp70, increasing its normally slow rate of ATP hydrolysis. When ATP is hydrolyzed to ADP the binding pocket of Hsp70 closes, tightly binding the now-trapped peptide chain. Further speeding ATP hydrolysis are the so-called J-domain cochaperones: primarily Hsp40 in eukaryotes, and DnaJ in prokaryotes. These cochaperones dramatically increase the ATPase activity of Hsp70 in the presence of interacting peptides.
Rocha-Méndez et al. (2026) report evidence from the study of mitochondrial genomes of European fallow deers from the Neumark-Nord sites (Germany) indicative of loss of genetic diversity of the species since the Pleistocene, recovering the studied extinct population from a single Eemian locality with as much genetic diversity as seen in extant population with a Eurasian range. Chung & Cho (2026) describe new antler remains of Elaphurus formosanus from the Pleistocene of Taiwan and support recognition of the species as distinct. Amanova, Drucker & Fontana (2026) reconstruct the ecology and habitat use of red deers from the Epigravettian sequence of Riparo Tagliente (Italy) on the basis of the study of carbon and oxygen isotopic composition of their tooth enamel, reporting evidence of a diet based on C3 plants and life in the landscape dominated by open woodland environments. Kubo, Yamazaki & Taniguchi (2026) reconstruct the diet of early to mid-Holocene sika deers from the Iyai Rockshelter Site (Japan) on the basis of the study on their tooth wear texture, reporting evidence of abrasive food in their diets and short-term temporal changes in foraging conditions. Martínez-Polanco (2026) determines diet of extant Neotropical deer (including local dietary variation within species) on the basis of the study of their tooth wear, providing reference data that can be used to determine diets of fossil deer and other small- to medium-sized ungulates.
In 1998, after 38 years of ownership, Monaghan announced his retirement, sold 93 percent of the company to Bain Capital, Inc. for about $1 billion, and ceased being involved in day-to-day operations of the company. A year later, the company named Dave Brandon as its CEO.
Sources: en.wikipedia.org
The calculations involve several steps and include an intermediate value called the "radiocarbon age", which is the age in "radiocarbon years" of the sample: an age quoted in radiocarbon years means that no calibration curve has been used − the calculations for radiocarbon years assume that the atmospheric 14C/12C ratio has not changed over time. Calculating radiocarbon ages also requires the value of the half-life for 14C. In Libby's 1949 paper he used a value of 5720 ± 47 years, based on research by Engelkemeir et al. This was remarkably close to the modern value, but shortly afterwards the accepted value was revised to 5568 ± 30 years, and this value was in use for more than a decade. It was revised again in the early 1960s to 5,730 ± 40 years, which meant that many calculated dates in papers published prior to this were incorrect (the error in the half-life is about 3%). For consistency with these early papers, it was agreed at the 1962 Radiocarbon Conference in Cambridge (UK) to use the "Libby half-life" of 5568 years. Radiocarbon ages are still calculated using this half-life, and are known as "Conventional Radiocarbon Age". Since the calibration curve (IntCal) also reports past atmospheric 14C concentration using this conventional age, any conventional ages calibrated against the IntCal curve will produce a correct calibrated age.
=== Pharmacodynamics === In vitro, cannabidiol has low affinity for, and acts as a negative allosteric modulator of the CB1 cannabinoid receptor Cannabidiol may be an antagonist of GPR55, a G protein-coupled receptor and putative non-homologous CB3 cannabinoid receptor shown by in vitro studies to be widely distributed in the brain. Cannabidiol may interact with various neurotransmitters, such as serotonin, dopamine, and GABA. As of 2024, the cellular effects and mechanisms of cannabidiol in vivo are unknown, as research to date has been inconclusive and based on laboratory studies. The anticonvulsant effects provided by cannabidiol (Epidiolex) in people with certain forms of epilepsy do not appear to involve cannabinoid receptors. A possible mechanism for the effects of cannabidiol on seizures is by affecting the neuronal movement of calcium in brain structures involved in the excessive electrical activity of seizures.
== Foundation == Galway University Foundation (GUF) was established in 1998 with the intention of generating financial support for the university from private individuals and institutions. It nurtures relationships with donors for whom the university's approach to education appeals. The Foundation has many 'Priority Projects' in development.
== Further reading == Schüring, J.; Schulz, H. D.; Fischer, W. R.; Böttcher, J.; Duijnisveld, W. H., eds. (1999). Redox: Fundamentals, Processes and Applications. Heidelberg: Springer-Verlag. p. 246. hdl:10013/epic.31694.d001. ISBN 978-3-540-66528-1. Tratnyek, Paul G.; Grundl, Timothy J.; Haderlein, Stefan B., eds. (2011). Aquatic Redox Chemistry. ACS Symposium Series. Vol. 1071. doi:10.1021/bk-2011-1071. ISBN 978-0-8412-2652-4.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.